Biomm S.A (SA:BIOM3) — Market Cap & Net Worth
Market Cap & Net Worth: Biomm S.A (BIOM3)
Biomm S.A (SA:BIOM3) has a market capitalization of $176.68 Million (R$900.42 Million) as of June 20, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #17133 globally and #162 in its home market, demonstrating a -6.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomm S.A's stock price R$6.58 by its total outstanding shares 136841532 (136.84 Million). Review total liabilities of Biomm S.A to assess the company's total debt and financial obligations.
Biomm S.A Market Cap History: 2015 to 2026
Biomm S.A's market capitalization history from 2015 to 2026. Data shows change from $150.36 Million to $176.68 Million (-0.03% CAGR).
Biomm S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomm S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.00x
Biomm S.A's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $255.08 Million | $103.00K | -$38.13 Million | 2476.53x | N/A |
| 2018 | $219.37 Million | $1.57 Million | -$42.56 Million | 140.08x | N/A |
| 2019 | $332.95 Million | $8.94 Million | -$55.81 Million | 37.23x | N/A |
| 2020 | $435.25 Million | $58.67 Million | -$70.77 Million | 7.42x | N/A |
| 2021 | $348.52 Million | $107.09 Million | -$80.26 Million | 3.25x | N/A |
| 2022 | $182.32 Million | $104.95 Million | -$92.56 Million | 1.74x | N/A |
| 2023 | $155.20 Million | $118.19 Million | -$81.14 Million | 1.31x | N/A |
| 2024 | $286.23 Million | $142.91 Million | -$77.24 Million | 2.00x | N/A |
Competitor Companies of BIOM3 by Market Capitalization
Companies near Biomm S.A in the global market cap rankings as of June 20, 2026.
Key companies related to Biomm S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Biomm S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Biomm S.A's market cap moved from $150.36 Million to $ 176.68 Million, with a yearly change of -0.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$176.68 Million | -8.86% |
| 2025 | R$193.86 Million | -32.27% |
| 2024 | R$286.23 Million | +84.43% |
| 2023 | R$155.20 Million | -14.87% |
| 2022 | R$182.32 Million | -47.69% |
| 2021 | R$348.52 Million | -19.93% |
| 2020 | R$435.25 Million | +30.73% |
| 2019 | R$332.95 Million | +51.77% |
| 2018 | R$219.37 Million | -14.00% |
| 2017 | R$255.08 Million | +47.29% |
| 2016 | R$173.19 Million | +15.18% |
| 2015 | R$150.36 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Biomm S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $176.68 Million USD |
| MoneyControl | $176.68 Million USD |
| MarketWatch | $176.68 Million USD |
| marketcap.company | $176.68 Million USD |
| Reuters | $176.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more